DK3067043T3 - Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer - Google Patents

Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer Download PDF

Info

Publication number
DK3067043T3
DK3067043T3 DK16157767.1T DK16157767T DK3067043T3 DK 3067043 T3 DK3067043 T3 DK 3067043T3 DK 16157767 T DK16157767 T DK 16157767T DK 3067043 T3 DK3067043 T3 DK 3067043T3
Authority
DK
Denmark
Prior art keywords
superstructures
arb
nep
blockers
inhibitors
Prior art date
Application number
DK16157767.1T
Other languages
English (en)
Inventor
Jiahui Hu
Natrajan Kumaraperumal
Alan Edward Royce
Colleen Ruegger
Erika Aina Zannou
Suliman Al-Fayoumi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3067043(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3067043T3 publication Critical patent/DK3067043T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16157767.1T 2007-11-06 2008-11-04 Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer DK3067043T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06
EP10173506.6A EP2295035B1 (en) 2007-11-06 2008-11-04 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Publications (1)

Publication Number Publication Date
DK3067043T3 true DK3067043T3 (da) 2023-02-27

Family

ID=40451030

Family Applications (3)

Application Number Title Priority Date Filing Date
DK16157767.1T DK3067043T3 (da) 2007-11-06 2008-11-04 Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer
DK08848154.4T DK2217205T3 (da) 2007-11-06 2008-11-04 Dobbeltvirkende farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase- (nep) inhibitor
DK10173506.6T DK2295035T3 (da) 2007-11-06 2008-11-04 Dobbeltvirkende farmaceutiske sammensætninger baserede på superstrukturer af angiotensinreceptor antagonister/blokkere (arb) og neutral endopeptidase (nep) inhibitorer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK08848154.4T DK2217205T3 (da) 2007-11-06 2008-11-04 Dobbeltvirkende farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase- (nep) inhibitor
DK10173506.6T DK2295035T3 (da) 2007-11-06 2008-11-04 Dobbeltvirkende farmaceutiske sammensætninger baserede på superstrukturer af angiotensinreceptor antagonister/blokkere (arb) og neutral endopeptidase (nep) inhibitorer

Country Status (34)

Country Link
US (3) US20100267786A1 (da)
EP (4) EP2295035B1 (da)
JP (2) JP5653218B2 (da)
KR (2) KR101589317B1 (da)
CN (2) CN101848700A (da)
AR (1) AR069184A1 (da)
AU (1) AU2008324878B2 (da)
BR (1) BRPI0823505A2 (da)
CA (1) CA2703598C (da)
CL (1) CL2008003298A1 (da)
CY (2) CY1116280T1 (da)
DK (3) DK3067043T3 (da)
EC (1) ECSP10010160A (da)
ES (3) ES2536514T3 (da)
FI (1) FI3067043T3 (da)
GT (1) GT201000131A (da)
HK (3) HK1143529A1 (da)
HR (3) HRP20230178T3 (da)
HU (2) HUE028866T2 (da)
IL (3) IL262990B2 (da)
JO (1) JOP20080499B1 (da)
MA (1) MA31797B1 (da)
MX (1) MX2010004930A (da)
MY (1) MY153730A (da)
NZ (1) NZ584686A (da)
PE (2) PE20141072A1 (da)
PL (3) PL3067043T3 (da)
PT (3) PT2217205E (da)
RU (1) RU2493844C3 (da)
SG (1) SG185951A1 (da)
SI (3) SI2217205T1 (da)
TN (1) TN2010000200A1 (da)
TW (1) TWI484982B (da)
WO (1) WO2009061713A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
EA026989B1 (ru) 2013-02-14 2017-06-30 Новартис Аг Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
WO2015028941A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
MX2017007426A (es) 2014-12-08 2018-04-20 Crystal Pharmatech Co Ltd Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106389374A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
US20190054069A1 (en) * 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608220A (en) 1898-08-02 Mechanical movement
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
IL136142A0 (en) * 1997-11-17 2001-05-20 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
CZ297795B6 (cs) * 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
PL205715B1 (pl) 2000-07-19 2010-05-31 Novartis Ag Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
EP1648515B1 (en) 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
US20080227836A1 (en) 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
CA2628793C (en) 2005-11-07 2015-01-27 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
WO2007056324A2 (en) 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)

Also Published As

Publication number Publication date
HRP20160988T1 (hr) 2016-10-07
KR101589317B9 (ko) 2022-11-23
US20100267786A1 (en) 2010-10-21
IL249922A0 (en) 2017-03-30
JP2011503082A (ja) 2011-01-27
JP2015038069A (ja) 2015-02-26
MA31797B1 (fr) 2010-10-01
HUE028866T2 (en) 2017-01-30
IL262990B1 (en) 2023-06-01
RU2010123027A (ru) 2011-12-20
IL205208A0 (en) 2010-12-30
TN2010000200A1 (en) 2011-11-11
SI2295035T1 (sl) 2016-09-30
PE20091390A1 (es) 2009-10-13
PT3067043T (pt) 2023-03-01
EP2295035A2 (en) 2011-03-16
CY1117883T1 (el) 2017-05-17
EP4186491A1 (en) 2023-05-31
TW200936183A (en) 2009-09-01
CA2703598A1 (en) 2009-05-14
WO2009061713A1 (en) 2009-05-14
AU2008324878A1 (en) 2009-05-14
PT2217205E (pt) 2015-06-08
JOP20080499B1 (ar) 2022-09-15
PL3067043T3 (pl) 2023-05-08
EP2217205B1 (en) 2015-03-04
KR101700062B9 (ko) 2022-11-23
GT201000131A (es) 2012-04-30
EP3067043B1 (en) 2022-11-30
ECSP10010160A (es) 2010-06-29
JP5653218B2 (ja) 2015-01-14
HK1143529A1 (en) 2011-01-07
NZ584686A (en) 2013-03-28
HK1149721A1 (zh) 2011-10-14
HUE061321T2 (hu) 2023-06-28
EP3067043A1 (en) 2016-09-14
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
HK1224195A1 (zh) 2017-08-18
KR20150139624A (ko) 2015-12-11
US20210085631A1 (en) 2021-03-25
KR20100085087A (ko) 2010-07-28
SG185951A1 (en) 2012-12-28
CA2703598C (en) 2016-08-09
PL2217205T3 (pl) 2015-07-31
AU2008324878B2 (en) 2013-04-18
MY153730A (en) 2015-03-13
CN101848700A (zh) 2010-09-29
CN103251587A (zh) 2013-08-21
ES2536514T3 (es) 2015-05-26
DK2217205T3 (da) 2015-05-11
ES2587336T3 (es) 2016-10-24
HRP20230178T3 (hr) 2023-03-31
EP2217205A1 (en) 2010-08-18
KR101589317B1 (ko) 2016-01-28
PE20141072A1 (es) 2014-09-10
BRPI0823505A2 (pt) 2015-06-16
PL2295035T3 (pl) 2016-11-30
SI2217205T1 (sl) 2015-10-30
AR069184A1 (es) 2010-01-06
MX2010004930A (es) 2010-05-27
CL2008003298A1 (es) 2009-06-26
EP2295035A3 (en) 2012-08-08
DK2295035T3 (da) 2016-08-29
PT2295035T (pt) 2016-08-22
EP2295035B1 (en) 2016-05-18
KR101700062B1 (ko) 2017-01-26
TWI484982B (zh) 2015-05-21
SI3067043T1 (sl) 2023-04-28
HRP20150459T1 (hr) 2015-07-17
RU2493844C2 (ru) 2013-09-27
IL205208A (en) 2017-01-31
IL262990B2 (en) 2023-10-01
CY1116280T1 (el) 2017-03-15
IL262990A (en) 2018-12-31
FI3067043T3 (fi) 2023-03-18
ES2939163T3 (es) 2023-04-19

Similar Documents

Publication Publication Date Title
DK3067043T3 (da) Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer
DK2340828T3 (da) Farmaceutiske kombinationer af en angiotensinreceptor-antagonist og en nep-hæmmer
DK2346552T4 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DE602007010533D1 (de) Bildschirmstandfuß
DK1971862T3 (da) Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
DK2079688T3 (da) Glucagonreceptorantagonist-forbindelser, sammensætninger indeholdende sådanne forbindelser og deres farmaceutiske anvendelse
DK2557180T3 (da) Fremgangsmåder til påvisning af autoimmune lidelser
ATE465169T1 (de) Hemmstoffe des progesteron-rezeptors
DE602007011453D1 (de) Ladungszurückhaltungsschaltung zur zeitmessung
DE602008003491D1 (de) Projektionsbildanzeigegerät
BRPI0810926A2 (pt) Antagonista de crig
DE602007001170D1 (de) Projektionsanzeigegerät
DK2059246T3 (da) Terapeutiske sammensætninger omfattende en specifik endothelin-receptorantagonist og en PDE5-inhibitor
DK2320739T3 (da) Farmaceutiske sammensætninger og fremgangsmåder til stabilisering af disse
BRPI0817202A2 (pt) métodos e composições para detecção de ehrlichia chaffensis (vlpt)
DK2075404T3 (da) Indretning til indføring af mørtel
DK2303268T3 (da) Farmaceutiske sammensætninger baseret på kinin-B2-receptorantagonister og corticosteroider og anvendelser deraf
DK1820751T3 (da) Indretning til modtagelse af affald
DK1952757T3 (da) Databehandlingsanordning til behandling af måleværdier
DK2089711T3 (da) Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika
DE602007004817D1 (de) Bildanzeigevorrichtung
FI20075173A0 (fi) Yleisoptinen mittalaite
SE0601104L (sv) Anordning vid byggnadselement
ITFI20060049A1 (it) Display arabo
FR2913148B1 (fr) Dispositif de pontage